Acceso usuarios
The increase of life expectancy in oncologic patients and the rising interest on psychiatric and psychological aspects of the oncologic disease implie a growth in the demand of psychotherapeutic and psychopharmacologic interventions, most of them for depression. The wide spectrum of available interventions for the depressive disorders allows clinicians to choose treatments compatible with the oncologic ones, increasing quality of life of patients and their social setting. This paper reviews and comments the most important evidences compiled from the last ten years' scientific literature, offering a narrative review of the present situation.
